Ns1 Is a Key Protein in the Vaccine Composition to Protect Ifnar(-/-) Mice against Infection with Multiple Serotypes of African Horse Sickness Virus

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  de la Poza, Francisco ^a   Calvo Pinilla, Eva ^a,b   López Gil, Elena ^a   Marín López, Alejandro ^a   Mateos, Francisco ^a   Castillo Olivares, Javier ^b   Lorenzo, Gema ^a   Ortego, Javier ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria Consejo Superior de Investigaciones Científicas   (Spain)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN HORSE SICKNESS VIRUS VACCINE; NAKED DNA; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; PROTEIN VP2; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

AFRICAN HORSE SICKNESS VIRUS; AFRICAN HORSE SICKNESS VIRUS 4; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; BIOENGINEERING; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; EMBRYO; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA; REOVIRUS INFECTION; SEROTYPE; T LYMPHOCYTE ACTIVATION; VACCINATION; VIREMIA; VIRUS CELL INTERACTION; VIRUS RECOMBINANT; VIRUS VIRULENCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; BRAIN MAPPING; CASE-CONTROL STUDIES; CELL PHYSIOLOGICAL PHENOMENA; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; LONGITUDINAL STUDIES; MALE; MICE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEURAL NETWORKS (COMPUTER); NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; RATS;

EID: 84880719162     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070197     Document Type: Article

References (33)

1. Mellor PS, Hamblin C, (2004) African horse sickness. Vet Res 35: 445-466.
2. Howell PG, (1962) The isolation and identification of further antigenic types of African horsesickness virus. Onderstepoort Journal of Veterinary Research 29: 139-149.
3. McIntosh BM, (1958) Immunological types of horse sickness and their significance in immunization. Onderstepoort J Vet Res 27: 465-538.
4. Du Toit R, (1944) The transmission of bluetongue and horse sickness by Culicoides. Onderstepoort J Vet Sci Anim Ind 19: 7-16.
5. Manole V, Laurinmaki P, Van Wyngaardt W, Potgieter CA, Wright IM, et al. (2012) Structural insight into African horsesickness virus infection. J Virol 86: 7858-7866.
6. Grubman MJ, Lewis SA, (1992) Identification and characterization of the structural and nonstructural proteins of African horsesickness virus and determination of the genome coding assignments. Virology 186: 444-451.
7. Roy P (1996) Orbiviruses and their replication. In: B. N. Fields DMKPM, Howley, editors. Fields Virology. 3rd ed. Philadelphia Lippincott-Raven. 1709-1734.
8. van Staden V, Theron J, Greyling BJ, Huismans H, Nel LH, (1991) A comparison of the nucleotide sequences of cognate NS2 genes of three different orbiviruses. Virology 185: 500-504.
9. Belhouchet M, Mohd Jaafar F, Firth AE, Grimes JM, Mertens PP, et al. (2011) Detection of a fourth orbivirus non-structural protein. PLoS One 6: e25697.
10. Weyer CT, Quan M, Joone C, Lourens CW, MacLachlan NJ, et al. (2012) African horse sickness in naturally infected, immunised horses. Equine Vet J 45: 117-119.
11. Chiam R, Sharp E, Maan S, Rao S, Mertens P, et al. (2009) Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA). PLoS One 4: e5997.
12. Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek-Bankowska K, Chiam R, et al. (2011) A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. PLoS One 6: e16503.
13. Stone-Marschat MA, Moss SR, Burrage TG, Barber ML, Roy P, et al. (1996) Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4. Virology 220: 219-222.
14. Burrage TG, Trevejo R, Stone-Marschat M, Laegreid WW, (1993) Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2. Virology 196: 799-803.
15. Scanlen M, Paweska JT, Verschoor JA, van Dijk AA, (2002) The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant. Vaccine 20: 1079-1088.
16. Guthrie AJ, Quan M, Lourens CW, Audonnet JC, Minke JM, et al. (2009) Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. Vaccine 27: 4434-4438.
17. Andrew M, Whiteley P, Janardhana V, Lobato Z, Gould A, et al. (1995) Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. Vet Immunol Immunopathol 47: 311-322.
18. Janardhana V, Andrew ME, Lobato ZI, Coupar BE, (1999) The ovine cytotoxic T lymphocyte responses to bluetongue virus. Res Vet Sci 67: 213-221.
19. Calvo-Pinilla E, Navasa N, Anguita J, Ortego J, (2012) Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus. PLoS One 7: e34735.
20. Calvo-Pinilla E, Rodriguez-Calvo T, Sevilla N, Ortego J, (2009) Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection. Vaccine 28: 437-445.
21. Calvo-Pinilla E, Nieto JM, Ortego J, (2010) Experimental oral infection of bluetongue virus serotype 8 in type I interferon receptor-deficient mice. J Gen Virol 91: 2821-2825.
22. Franceschi V, Capocefalo A, Calvo-Pinilla E, Redaelli M, Mucignat-Caretta C, et al. (2011) Immunization of knock-out alpha/beta interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen. Vaccine 29: 3074-3082.
23. Jabbar TK, Calvo-Pinilla E, Mateos F, Gubbins S, Bin-Tarif A, et al. (2013) Protection of IFNAR (-/-) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2. PLoS One 8: e60574.
24. Kyle JL, Balsitis SJ, Zhang L, Beatty PR, Harris E, (2008) Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology 380: 296-303.
25. Ma G, Eschbaumer M, Said A, Hoffmann B, Beer M, et al. (2012) An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. PLoS One 7: e34425.
26. Ohka S, Igarashi H, Nagata N, Sakai M, Koike S, et al. (2007) Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. J Virol 81: 7902-7912.
27. Mortola E, Noad R, Roy P, (2004) Bluetongue virus outer capsid proteins are sufficient to trigger apoptosis in mammalian cells. J Virol 78: 2875-2883.
28. Roy P, Bishop DH, Howard S, Aitchison H, Erasmus B, (1996) Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge. J Gen Virol 77 (Pt 9): 2053-2057.
29. Martinez-Torrecuadrada JL, Diaz-Laviada M, Roy P, Sanchez C, Vela C, et al. (1996) Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7. J Gen Virol 77 (Pt 6): 1211-1221.
30. El Garch H, Crafford JE, Amouyal P, Durand PY, Edlund Toulemonde C, et al. (2012) An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses. Vet Immunol Immunopathol 149: 76-85.
31. Eschbaumer M, Keller M, Beer M, Hoffmann B (2011) Epizootic hemorrhagic disease virus infection of type I interferon receptor deficient mice. Vet Microbiol.
32. von Teichman BF, Dungu B, Smit TK, (2010) In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6. Vaccine 28: 6505-6517.
33. Pretorius A, Van Kleef M, Van Wyngaardt W, Heath J, (2012) Virus-specific CD8(+) T-cells detected in PBMC from horses vaccinated against African horse sickness virus. Vet Immunol Immunopathol 146: 81-86.